The most common reasons for trial ineligibility in both analyses were low albumin or prealbumin levels (2281 patients [15.5%]), thrombocytopenia (1369 patients [9.3%]), and elevated bilirubin levels (1293 patients [8.8%]) (eFigure 4 in the Supplement). Here, TTR is linked to Thrombocytopenia.